Skip to main content

vibativ

Generic: telavancin

vibativ: sourced relationships with 1 company · 1 FDA decision.

vibativ evidence translation

What we can confirm

What it means

Source-backed records connect vibativ to CPIX; that link alone does not prove the drug works.

What to watch

Watch for new trials or company disclosures after the FDA record.
BioSniper AIPage evidence connected

Prepared research question

How could vibativ → CPIX affect its developer, and what evidence supports the link?

Run cited research

Traceable citations · Unknowns marked

Dated Pipeline Records (1)
CompanyDated record stage
CUMBERLAND PHARMACEUTICALS INC (CPIX)
Reported 2009-09-11 · Current development: unknownSource
Approved
FDA Decisions1 records
Approval1 INDICATIONS AND USAGE VIBATIV is a lipoglycopeptide antibacterial drug indicated for the treatment of the following infections in adult patients caused by designated susceptible bacteria: Complicated skin and skin structure infections (cSSSI) ( 1.1 ) Hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP) caused by susceptible isolates of Staphylococcus aureus . VIBATIV should be reserved for use when alternative treatments are not suitable. ( 1.2 ) To reduce the developmen(CPIX)FDA ↗
NDA022110Type 1 - New Molecular EntityStandardIntravenousPowder

Frequently asked questions

Which companies have sourced relationships with vibativ?

vibativ has dated SEC/FDA relationship records for CUMBERLAND PHARMACEUTICALS INC.

What is vibativ's latest FDA decision?

The most recent tracked FDA decision for vibativ is Approval for 1 INDICATIONS AND USAGE VIBATIV is a lipoglycopeptide antibacterial drug indicated for the treatment of the following infections in adult patients caused by designated susceptible bacteria: Complicated skin and skin structure infections (cSSSI) ( 1.1 ) Hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP) caused by susceptible isolates of Staphylococcus aureus . VIBATIV should be reserved for use when alternative treatments are not suitable. ( 1.2 ) To reduce the developmen, dated September 11, 2009.